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OBJECTIVES: The aim of this study was to evaluate cardiovascular autonomic function in a rodent obesity model
induced by monosodium glutamate injections during the first seven days of life.
METHOD: The animals were assigned to control (control, n = 10) and monosodium glutamate (monosodium
glutamate, n = 13) groups. Thirty-three weeks after birth, arterial and venous catheters were implanted for
arterial pressure measurements, drug administration, and blood sampling. Baroreflex sensitivity was evaluated
according to the tachycardic and bradycardic responses induced by sodium nitroprusside and phenylephrine
infusion, respectively. Sympathetic and vagal effects were determined by administering methylatropine and
propranolol.
RESULTS: Body weight, Lee index, and epididymal white adipose tissue values were higher in the monosodium
glutamate group in comparison to the control group. The monosodium glutamate-treated rats displayed insulin
resistance, as shown by a reduced glucose/insulin index (-62.5%), an increased area under the curve of total insulin
secretion during glucose overload (39.3%), and basal hyperinsulinemia. The mean arterial pressure values were
higher in the monosodium glutamate rats, whereas heart rate variability (.7 times), bradycardic responses (.4
times), and vagal (,38%) and sympathetic effects (,36%) were reduced as compared to the control group.
CONCLUSION: Our results suggest that obesity induced by neonatal monosodium glutamate treatment impairs
cardiac autonomic function and most likely contributes to increased arterial pressure and insulin resistance.
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INTRODUCTION
The metabolic syndrome is an emerging global epidemic
characterized by the clustering of metabolic abnormalities,
such as glucose intolerance and/or type 2 diabetes, dys-
lipidemia, hypertension, and abdominal obesity, which lead
to increased cardiovascular-related mortality (1). Weight
gain usually leads to insulin resistance, compensatory hy-
perinsulinemia, and hypertension through parallel mechanisms
that may be connected (2). In normotensive obese subjects,
changes in sympathetic nervous system modulation correlate
with insulin resistance, and decreased heart rate variabilitymay
partly account for the increased cardiovascular risk in these
subjects (3).
In the experimental setting, animal models have been
used to gain an understanding of obesity-related metabolic
disorders, including models of surgical and pharmacologi-
cal induction of obesity in mice (4) and rats (5,6). In mice,
the neonatal administration of monosodium glutamate
(MSG) causes damage in the hypothalamic and circumven-
tricular areas and results in several neuroendocrine and
metabolic abnormalities (7), including hypophagia, obesity,
hypoactivity, delayed puberty, and elevated plasma corti-
costerone levels (8). Furthermore, stunted growth, increased
adipose tissue stores, and a marked increase in plasma
triglycerides have been noted in rats (9).
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Although many of the above characteristics are similar to
the characteristics of metabolic syndrome as it occurs in
humans, the few studies that have evaluated cardiovascular
changes in the MSG-induced obesity animal model have
reported conflicting results. Female, but not male, MSG-
treated rats exhibit systolic hypotension, and no changes in
heart rate were obtained using the indirect tail-cuff method
(10). These results suggest that gender may be important in
the MSG response. Moreover, reduced vascular responsive-
ness to alpha-adrenergic stimulation was observed in MSG-
treated rats (11). In a similar animal model, ventromedial
hypothalamic lesions displayed massive obesity, insulin
resistance, low sympathetic activity, high parasympathetic
activity, and no changes in blood pressure (6). Although the
metabolic aspects of MSG-induced obesity have been ex-
tensively examined, it has not been studied in detail con-
cerning cardiovascular autonomic function. Thus, the
present study was designed to evaluate cardiovascular
autonomic function in rats that received MSG neonatal
treatment and the potential relationship between this
treatment and metabolic abnormalities.
METHODS
Animals
The experiments were performed using 23 male Wistar
rats obtained from the animal facility at the Federal
University of Health Sciences of Porto Alegre (Porto
Alegre, Brazil). The experimental protocol was approved
by the Institutional Animal Care and Use Committee at the
Federal University of Health Sciences of Porto Alegre, and
this investigation was conducted in accordance with the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1985).
During the first seven days of life, 2 mg/kg of MSG
(monosodium glutamate, Sigma, USA) or saline in a similar
volume was injected subcutaneously into the rats once per day,
as previously described (4). The rats were randomly assigned to
either the control (n=10) or MSG-injected (MSG, n=13) group.
The pupswereweaned on the 21st day of life and kept in plastic
cages (five per cage) in a temperature-controlled room (22 C˚)
with a 12-hour dark-light cycle (light 07:00-19:00 h). The
animals were fed standard laboratory chow and water ad
libitum, and their body weights were monitored weekly for 33
weeks. The Lee index (b.w.1/3 in g/naso-anal length in mm)
was measured during the final evaluation.
Hemodynamic assessments
Thirty-three weeks after birth, two catheters filled with
0.06 mL of saline were implanted into the femoral artery of
each anesthetized rat (80 mg/kg ketamine and 12 mg/kg
xylazine, i.p.). Twenty-four hours later, the arterial cannula
was connected to a strain gauge transducer (Blood Pressure
XDCR; Kent Scientific, Torrington, CT, USA), and the
arterial pressure (AP) signals were recorded over a 30-
minute period in conscious animals using a microcomputer
equipped with an analog-to-digital converter board
(WinDaq, 2 kHz, DATAQ, Springfield, OH, USA). The
recorded data were analyzed on a beat-by-beat basis to
quantify any changes in the mean AP (MAP) and heart rate
(HR). The overall variability of the pulse interval and
systolic AP in the time domain was assessed by computing
the standard deviation (SD) of the time series (12-14).
Baroreflex sensitivity
Sequential bolus injections (0.1 mL) of increasing doses of
phenylephrine (0.25 to 32 mg/kg) and sodium nitroprusside
(0.05 to 1.6 mg/kg) were given to induce increases or
decreases in MAP pressure responses (for each drug),
ranging from 5 to 40 mm Hg. Baroreflex sensitivity is
expressed as bradycardic (BR) and tachycardic (TR) res-
ponses in beats per minute per millimeter of mercury, as
described elsewhere (12-14).
Autonomic evaluation
The vagal and sympathetic effects were both studied by
administering injections of methylatropine (3 mg/kg IV,
Sigma) and propranolol (4 mg/kg IV, Sigma) at a maximal
volume per injection of 0.2 mL. On the first day of the study,
the resting HR was recorded in unrestrained rats that were
kept in their own cages. Immediately after the resting HR
was recorded, methylatropine was injected. Because the HR
response to methylatropine reaches its peak within 10 to 15
minutes, this time interval was standardized before the HR
measurement was taken. On the second day of the study,
propranolol was administered. The vagal effect (VE) was
evaluated as the difference between the maximum HR after
the methylatropine injection and the resting HR. The
sympathetic effect (SE) was evaluated as the difference
between the resting HR and the minimum HR after the
propranolol injection (14,15).
Metabolic measurements
One day after the last cardiovascular evaluation (6-h
fasting), blood was collected from the arterial cannula for
plasma glucose and insulin evaluation. An oral glucose
tolerance test (OGTT, 0.5 g/kg oral) was also performed
(16). The blood samples (0.5 mL) were collected through the
arterial catheter at baseline and 5, 15, 30 and 60 min after the
oral glucose test. Using a glucose oxidase kit (Boehringer
Mannheim, Mannheim, Germany), plasma samples were
obtained for further glucose analysis. For insulin measure-
ments, a radioimmunoassay was performed using anti-
human insulin antibodies (Sigma) and 125I-human insulin
as the radiolabel (Amersham). After the evaluations, the
animals were sacrificed, and a fat mass (white adipose
tissue) and lean mass (gastrocnemius and heart muscle)
were weighed from each animal.
Statistical analysis
The data are reported as the mean¡SEM, and Student’s
unpaired t-test was used to compare the values obtained
between groups. The insulin response to the glucose
overload was evaluated using the area under the curve.
Baroreflex sensitivity was evaluated using a regression
analysis of different groups, and the slopes were compared
using Tukey’s ANOVA as a post-hoc test. Pearson’s
correlation coefficient was used to identify associations
between variables. Differences were considered statistically
significant when p,0.05.
RESULTS
The body weight measurements increased in the MSG
group (375¡6 g) after 33 weeks of follow-up in comparison
to the control group (355¡5 g) (p= 0.03). The Lee index
values were also higher in the MSG group as compared to
the control group (325¡2 vs. 315¡2 body weight1/3 in g/
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naso-anal length in mm, respectively) (p= 0.04), and the
MSG group had a greater fat mass (evaluated by the
epididymal white adipose tissue) than the control group
(1.58¡0.02 vs. 1.7¡0.07 g, respectively) (p= 0.01). However,
the lean mass was similar between the control and MSG
groups, as evaluated by the weights of the gastrocnemius
(1.92¡0.11 vs. 2.02¡0.08 g in MSG and control, respec-
tively) (p= 0.451) and heart muscles (1.17¡0.02 vs.
1.17¡0.03 g in MSG and control, respectively) (p= 1.00).
MSG treatment induced a state of insulin resistance, as
demonstrated by the plasma insulin levels during the OGTT
(Figure 1A). Furthermore, increased levels of fasting plasma
glucose (5.13¡0.79 mmol/L, p=0.03) and plasma insulin
(267¡29 pmol/L, p=0.02) were observed in theMSG-treated
animals as compared to the control group (3.18¡0.24 mmol/
l, and 159¡22 pmol/L, respectively). As a result, the
glucose/insulin index values were significantly lower in
the MSG group as compared to the control group (11.9¡0.12
vs. 32.2¡0.08 mmol/pmol x1000, respectively) (p=0.02).
The area under the curve for plasma insulin during the
OGTT (Figure 1B) was higher for MSG-treated rats
(22,685¡3,184 pmol/L/60 min) as compared to control
animals (13,729¡2,527 pmol/L/60 min), (p=0.05), confirm-
ing a higher level of insulin secretion in these animals in
response to the glucose overload.
Regarding the hemodynamic measurements, the MSG-
treated group displayed increased systolic, diastolic, and
mean arterial pressures as compared to the control group;
however, the systolic arterial pressure variability was
similar between groups (Table 1). Although the heart rate
was similar between the experimental groups, heart rate
variability was reduced in the MSG-treated animals in
comparison to the control animals (Table 1). By plotting the
results obtained from all of the control and MSG animals, it
was possible to identify a positive correlation between
plasma insulin and mean AP (r = 0.69, p = 0.04), as shown in
Figure 2. However, there was no relationship between
plasma glucose and mean AP (r = 0.19, p= 0.47).
Baroreflex sensitivity, as evaluated by BR, was reduced in
the MSG-treated animals as compared to the control animals,
although no differences were observed in the TR between the
experimental groups (Table 1). Furthermore, the vagal and
sympathetic effects were reduced in the MSG-treated rats as
compared to the control rats, as shown in Figure 3.
DISCUSSION
The main finding of the present study was that MSG
treatment induced metabolic (increases in body weight, the
Lee index, fat mass, hyperinsulinemia, and the insulin
response to OGTT) and cardiovascular (increased baseline
arterial pressure) changes that were most likely associated
with impairments in the autonomic control of circulation
and were manifested as reduced heart rate variability,
baroreflex sensitivity, and vagal and sympathetic effects. In
addition, the high blood pressure values observed were
positively correlated with insulin levels.
Insights into the etiology, pathophysiology, and pharma-
cological treatment of human obesity have arisen from the
study of animal models. However, animal obesity models
differ widely in the type and extent of obesity. For example,
these models are based on environmental factors, (e.g., high-
fat diet-induced obesity), spontaneous mutants (i.e., ob/ob
and/or db/db mice), genetically engineered animals (e.g.,
mice with melanocortin receptor subtype-4 gene disruption
(knock-out)), or mechanical intervention (e.g., chemical or
electrical lesions in the ventromedial hypothalamus) and
demonstrate different metabolic, hemodynamic, and hor-
monal results (17).
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Figure 1 - Plasma insulin levels (A) during the OGTT in the control
(C) and monosodium glutamate-treated (MSG) rats. In detail, the
insulin area under the curve (IArea) for the control and MSG
groups (B). * p=0.05.
Table 1 - Hemodynamic and autonomic measurements in
the control (C) and MSG-treated (MSG) groups.
Control MSG
SAP (mm Hg) 139¡2 147¡2*
DAP (mm Hg) 92¡2 99¡2*
MAP (mm Hg) 112¡1 121¡2*
HR (bpm) 352¡11 330¡11
SAP VAR (mm Hg) 6.0¡0.3 6.1¡0.6
HR VAR (bpm) 31.8¡1.8 4.3¡1.6*
TR (bpm/mm Hg) 2.5¡0.6 2.1¡0.5
BR (bpm/mm Hg) -1.4¡0.3 -0.3¡0.5*
Values are expressed as the mean¡SEM. SAP - Systolic arterial pressure;
DAP - Diastolic arterial pressure; MAP - Mean arterial pressure; SAP VAR -
Systolic arterial pressure variability evaluated according to the standard
deviation; HR - Heart rate; HR VAR – Heart rate variability evaluated
according to the standard deviation. *p,0.05 vs. control group.
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Figure 2 - Correlation between plasma insulin and mean arterial
pressure (MAP) in the control (C) and monosodium glutamate-
treated (MSG) rats (r = 0.69, p=0.04).
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The neonatal administration of MSG induces obesity in
rodents through neuronal damage to the arcuate nucleus-
median eminence region (4). This experimental model be-
haves differently from genetically obese and aurothioglu-
cose-induced (auTG) obese rats (18), as it results in in-
creased lipid mass and mild body weight increases without
hyperphagia. In our experiments, increases in body weight,
Lee index values, and adipose tissue were observed in MSG-
treated rats as compared to control animals, although the
lean mass measurements were similar between groups.
Consistent with these results, other studies have shown
similar changes in these parameters. Ribeiro Braga et al. (19)
showed that higher doses of MSG (4 mg/g of body weight)
induced increases in carcass fat, cellular size, and weight of
the epididymal adipose tissue. In another study (20), MSG
treatment (2 mg/g of body weight) during the first four
days after birth induced greater retroperitoneal fat mass in
comparison to control rats. Moreover, recently published
data demonstrated that MSG treatment during the first five
postnatal days induced increased fat deposits and hyperten-
sion in rats (21).
In the early phase of obesity establishment, normal
plasma glucose associated with hyperinsulinemia (22) has
been observed, which indicates that insulin resistance is
present and that the high insulin levels may be com-
pensatory (2,23). Other authors have shown similar results
concerning hyperinsulinemia and insulin resistance, sug-
gesting that there is an important decrease in the insulin-
stimulated IRS/PI3K/Akt pathway in muscle, which may
have an important role in the insulin resistance state (24). In
a similar vein, de Souza et al. (25) showed that the hy-
perinsulinemia observed in MSG-obese rats is, at least in
part, a consequence of the direct hypersecretion of ß cells
and that chronic aerobic exercise is able to partially coun-
teract the hyperinsulinemic state.
The present study found that MSG treatment during the
neonatal period induced a slight increase in arterial pressure
(,8%) in conscious adult rats. In accordance with these data,
the study by Cunha et al. (21) demonstrated that the admin-
istration of MSG to rats resulted in neuroendocrine obesity and
a moderate level of hypertension. Interestingly, in this work,
the mean arterial pressure values were positively correlated
with the insulin plasma levels, suggesting a cardio-metabolic
interaction. Several hypotheses have been postulated to explain
the link between hypertension and insulin resistance. Rodents
chronically fed high-carbohydrate diets (26,27) or chronically
infused with exogenous insulin to produce hyperinsulinemia
(28) showed increased blood pressure levels, although chronic
insulin infusion failed to increase blood pressure measure-
ments in dogs (29). However, acute (1 to 2 h) insulin infusion in
rats (30) and dogs (31) has been shown to increase blood
pressure, which is most likely the result of sympathetic
activation (32) and sodium retention during acute hyperinsu-
linemia. This rise in blood pressure is not generally sustained
because it is overridden by the vasodilator action of insulin,
which is rapidly sensed by baroreceptors, and a counter-
balancing increase in vasodilation returns the blood pressure to
normal. Although these studies may provide insight into the
potential role of insulin in hypertension, the quantitative
importance of hyperinsulinemia in the etiology of hypertension
has not yet been established.
To further explore the mechanisms involved in the cardio-
metabolic changes observed in animals treated with MSG,
we analyzed the autonomic control of circulation. It is well
known that decreased baroreflex sensitivity is a marker of
an increased risk of sudden death in patients after myo-
cardial infarction (33), and this measurement has also been
associated with increased arterial pressure, myocardial
damage, renal lesions, and arterial remodeling (34,35).
Moreover, there is some evidence correlating the decrease
in baroreflex function with body fat distribution, as patients
with abdominal obesity demonstrate a greater reduction in
baroreflex sensitivity than those with peripheral obesity
(35). In fact, children with primarily low baroreflex
sensitivity could have a greater predisposition to patholo-
gical arterial pressure elevation, and obesity has been
shown to be an additive factor to low baroreflex sensitivity
in the development of hypertension (36).
In the present study, the reduced bradycardic reflex in
MSG-treated rats could have been due to a decrease in the
vagal effect on the heart, which may have indicated
impairments in the vagal reserve used during heart rate
responses evoked by baroreceptors. Indeed, baroreflex-
mediated bradycardia is predominantly associated with
vagal actions on the heart. If a reduction in this activity
occurs, bradycardia is also reduced. Therefore, the attenua-
tion of the bradycardic response may have resulted from
reduced responsiveness of the sinus node to parasympa-
thetic modulation, as the vagal effect and (consequently) the
HR variability were reduced in MSG-treated rats. In
addition, HR variability has been strongly correlated with
the vagal indices of HR variability (37). Furthermore, similar
results were observed by Miller et al. (38), as rats fed a
fructose-rich diet displayed increased arterial pressure
levels and reduced baroreflex sensitivity associated with a
large reduction in vagal activity. Moreover, we previously
observed arterial pressure increases in female fructose-fed
rats as well as was a positive correlation between insulin
resistance and cardiac vagal effect attenuation (15).
In the present study, we observed a reduced sympathetic
effect that was not accompanied by changes in the basal HR
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or tachycardic responses to AP changes. Moreover, Rehorek
et al. (39) suggested that reduced sympathetic activity, as
expressed by decreased basal levels of norepinephrine, in
MSG-treated rats may be associated with reduced thermo-
genic responses, which could contribute to the development
of obesity. Some evidence has suggested a positive correla-
tion between excess weight gain and sympathetic hyper-
activity, which contributes to the development of hyper-
tension in both human and animal models (29,40). In fact,
Hellstrom (41) presented convincing evidence that the
development of a diverse group of diseases, such as
hypertension, diabetes and heart disease, is triggered by
increased sympathetic neural outflow, which results in
endothelial dysfunction, dyslipidemia, inflammation and
insulin resistance. Moreover, other data have suggested that
autonomic changes modulate hormonal and immune func-
tion by inducing the release of bioactive molecules, which
are likely involved in the development of cardiometabolic
profile changes (42,43). In the present work, the reduction in
parasympathetic cardiac activity predominated over other
sympathetic changes in the MSG group, as only the
bradycardic reflex (associated with impaired cardiac vagal
effect and variability) was reduced in this group. Together,
these results suggest that a relative sympathetic predomi-
nance may be associated with the increased arterial pressure
observed in MSG-treated rats.
Therefore, our results suggest that the obesity induced by
neonatal MSG treatment reduces cardiac autonomic func-
tion by most likely contributing to insulin resistance and an
increase in arterial pressure.
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